Scholarlink

Introduction <p>Fluid-filled intragastric balloon (FF-IGB) placement is an endoscopic bariatric procedure that effectively achieves short-term weight loss in patients affected by obesity. Comparative data among different balloon volumes are lacking. This study aimed to assess efficacy and safety of FF-IGB at different volumes.</p> Methods <p>A randomized single-center analysis over 156 patients undergoing FF-IGB at a volume of 500&#xa0;ml, 600&#xa0;ml, or 700&#xa0;ml with 6-month follow-up was conducted. Outcomes included postprocedural adverse events (AEs), early device removal for intolerance, evaluation of percentage of total weight loss (TWL%), excess weight loss (EWL%), and quality of life (QoL) at 6-month follow-up.</p> Results <p>The mean age of our cohort was 46.2&#xa0;years, and 69.2% were female. The mean BMI was 41.9&#xa0;kg/m<sup>2</sup>. Pain was the main adverse event being detected in 78.3% patients, followed by nausea (76.8%), and vomiting (50.7%). No serious AEs were reported. Ten patients required early balloon removal for epigastric pain, nausea, and vomiting. The FF-IGB volume was not associated with nausea (<i>p</i> = 0.657), vomiting (<i>p</i> = 0.487), pain (<i>p</i> = 0.182), or early removal (<i>p</i> = 0.988). Decrease in body mass index (BMI) after 6&#xa0;months was significant (mean BMI 35.24&#xa0;kg/m<sup>2</sup>, SD 7.17, <i>p</i> &lt; 0.001). Mean TWL% after 6&#xa0;months was 14.16. No significant difference between the FF-IGB volume and TWL% (<i>p</i> = 0.412) was detected. At 6&#xa0;months follow-up, the mean EWL% was 30.8 ± 23.3 with no differences among the three groups of different FF-IGB volumes (<i>p</i> = 0.733). A significant improvement of QoL was detected at 6&#xa0;months unrelated to the FF-IGB volume (<i>p</i> = 0.849).</p> Conclusion <p>FF-IGB placement resulted in significant weight loss over a 6-month period. No differences in TWL%, EWL%, rate of AEs, percentage of early device removal, and QoL were detected among the three groups with a different IGB volume. A 500&#xa0;ml filling volume could be “the magic number” as no significant benefits are achieved with a greater volume.</p> Key Points <p>• Fluid-filled intragastric balloon (FF-IGB) placement effectively achieves short-term weight loss in patients affected by obesity, but comparative data among different balloon volumes are lacking.</p> <p>• Weight-loss outcomes, adverse-event rates, and quality-of-life gains were identical across 500&#xa0;ml, 600&#xa0;ml, and 700&#xa0;ml balloon volumes.</p> <p>• A 500&#xa0;ml filling volume for fluid-filled intragastric balloons could be “the magic number,” as larger volumes confer no additional benefit.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intragastric Balloon for Treatment of Overweight and Obesity: Which Is the Best Filling Volume? A Single-Center Randomized Study

  • 期刊论文

  • 发表日期：

    2025年8月7日

查看全文
  • Salvatore Francesco Vadalà di Prampero,
  • Ica Bassu,
  • Marcello Fiorani,
  • Valentina Cosseddu,
  • Paola Bazzu,
  • Alessandro Zuddas,
  • Ilaria Simonelli,
  • Chiara Rocchi,
  • Marco Massidda,
  • Simona Masia,
  • Katarina Jankovic,
  • Nikola Panic,
  • Piero Giustacchini,
  • Guido Costamagna,
  • Milutin Bulajic

摘要

Introduction

Fluid-filled intragastric balloon (FF-IGB) placement is an endoscopic bariatric procedure that effectively achieves short-term weight loss in patients affected by obesity. Comparative data among different balloon volumes are lacking. This study aimed to assess efficacy and safety of FF-IGB at different volumes.

Methods

A randomized single-center analysis over 156 patients undergoing FF-IGB at a volume of 500 ml, 600 ml, or 700 ml with 6-month follow-up was conducted. Outcomes included postprocedural adverse events (AEs), early device removal for intolerance, evaluation of percentage of total weight loss (TWL%), excess weight loss (EWL%), and quality of life (QoL) at 6-month follow-up.

Results

The mean age of our cohort was 46.2 years, and 69.2% were female. The mean BMI was 41.9 kg/m2. Pain was the main adverse event being detected in 78.3% patients, followed by nausea (76.8%), and vomiting (50.7%). No serious AEs were reported. Ten patients required early balloon removal for epigastric pain, nausea, and vomiting. The FF-IGB volume was not associated with nausea (p = 0.657), vomiting (p = 0.487), pain (p = 0.182), or early removal (p = 0.988). Decrease in body mass index (BMI) after 6 months was significant (mean BMI 35.24 kg/m2, SD 7.17, p < 0.001). Mean TWL% after 6 months was 14.16. No significant difference between the FF-IGB volume and TWL% (p = 0.412) was detected. At 6 months follow-up, the mean EWL% was 30.8 ± 23.3 with no differences among the three groups of different FF-IGB volumes (p = 0.733). A significant improvement of QoL was detected at 6 months unrelated to the FF-IGB volume (p = 0.849).

Conclusion

FF-IGB placement resulted in significant weight loss over a 6-month period. No differences in TWL%, EWL%, rate of AEs, percentage of early device removal, and QoL were detected among the three groups with a different IGB volume. A 500 ml filling volume could be “the magic number” as no significant benefits are achieved with a greater volume.

Key Points

• Fluid-filled intragastric balloon (FF-IGB) placement effectively achieves short-term weight loss in patients affected by obesity, but comparative data among different balloon volumes are lacking.

• Weight-loss outcomes, adverse-event rates, and quality-of-life gains were identical across 500 ml, 600 ml, and 700 ml balloon volumes.

• A 500 ml filling volume for fluid-filled intragastric balloons could be “the magic number,” as larger volumes confer no additional benefit.